Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DB25FZS97
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $51,736
Award facts
- Contract value 100% obligated
- $51,736.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $51,736.20 to DMS Pharmaceutical Group Inc. on September 26, 2025, for the supply of Xtandi 40 mg capsules (120-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this work at its Park Ridge location. The contract employs firm fixed-price pricing with no set-aside designation and is scheduled for completion by September 29, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, a $499,999,999 single-award contract valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting military health facility operations globally.
Xtandi (enzalutamide) is a prescription medication used in the treatment of prostate cancer, reflecting DMS Pharmaceutical Group's established role as a critical supplier of oncology and specialty pharmaceuticals to the Department of Defense healthcare system. The company's federal contract portfolio demonstrates consistent success in securing pharmaceutical delivery orders across multiple therapeutic categories, including prescription medications, biologics, vaccines, and medical consumables. As a woman-owned small business with SAM.gov registration since 2001, DMS Pharmaceutical Group has leveraged its established relationships and broad pharmaceutical product capabilities to maintain significant federal market presence without relying on set-aside procurement vehicles.
Quick answers
Who was awarded contract SPE2DB25FZS97?
SPE2DB25FZS97 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 26, 2025.
How much is contract SPE2DB25FZS97 worth?
The government has obligated $51,736 on SPE2DB25FZS97.
Is contract SPE2DB25FZS97 an order under another contract?
Yes. SPE2DB25FZS97 is a delivery order under SPE2DB22D9244, an indefinite delivery contract.
Was contract SPE2DB25FZS97 competed?
The extent of competition for SPE2DB25FZS97 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award